Description Drug for Cancer treatment
ChemicalBook > CAS DataBase List > Bortezomib

Bortezomib

Description Drug for Cancer treatment
Product Name
Bortezomib
CAS No.
179324-69-7
Chemical Name
Bortezomib
Synonyms
dpba;MLM341;CS-1886;VELCADE;Radiciol;BortezMib;ortezomib;BORTEZOMIB;Brotezamide;BortezoMib R
CBNumber
CB8721789
Molecular Formula
C19H25BN4O4
Formula Weight
384.24
MOL File
179324-69-7.mol
More
Less

Bortezomib Property

Melting point:
122-124°C
Density 
1.214
RTECS 
ED7771666
storage temp. 
Inert atmosphere,Store in freezer, under -20°C
solubility 
Soluble in chloroform, dimethyl sulfoxide, ethanol and methanol.
pka
9.66±0.43(Predicted)
Stability:
Hygroscopic and Moisture Sensitive
CAS DataBase Reference
179324-69-7(CAS DataBase Reference)
More
Less

Safety

Risk Statements 
23/24/25-48/23/24/25
Safety Statements 
9-27-36/37-45-60
HazardClass 
6.1
HS Code 
29339900
Hazardous Substances Data
179324-69-7(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Hazard statements

H300Fatal if swallowed

H310Fatal in contact with skin

H330Fatal if inhaled

H372Causes damage to organs through prolonged or repeated exposure

Precautionary statements

P320Specific treatment is urgent (see … on this label).

P330Rinse mouth.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P405Store locked up.

More
Less

N-Bromosuccinimide Price

Alfa Aesar
Product number
J60378
Product name
Bortezomib, 99%
Packaging
10mg
Price
$213
Updated
2021/03/22
Alfa Aesar
Product number
J60378
Product name
Bortezomib, 99%
Packaging
25mg
Price
$374
Updated
2021/03/22
Cayman Chemical
Product number
10008822
Product name
Bortezomib
Purity
≥95%
Packaging
1mg
Price
$25
Updated
2021/03/22
Cayman Chemical
Product number
10008822
Product name
Bortezomib
Purity
≥95%
Packaging
5mg
Price
$56
Updated
2021/03/22
Cayman Chemical
Product number
10008822
Product name
Bortezomib
Purity
≥95%
Packaging
10mg
Price
$100
Updated
2021/03/22
More
Less

Bortezomib Chemical Properties,Usage,Production

Description

Bortezomib, a modified dipeptidyl boronic acid, is a therapeutic proteasome inhibitors used for the treatment of cancers. It is indicated for the treatment of relapsed multiple myeloma and mantle cell lymphoma. It is capable of inhibiting the mammalian 26S proteasome, which is important in regulating the intracellular concentration of specific proteins to maintain homeostasis within cells. The disruption of 26S proteasome function disrupts normal cellular homeostasis, leading to cytotoxic effect on various kinds of cancer cells. 

Drug for Cancer treatment

Bortezomib is a drug for treatment of hematopoietic malignancies with the appearance being white or white-like crystalline powder. It is easily soluble in dimethyl sulfoxide, ethanol, but insoluble in aqueous solution. This product is the reversible inhibitor of the mammal cell 26S proteasome chymotrypsin-like activity. 26S proteasome is a large protein complex which can degrade ubiquitin. Ubiquitin proteasome pathway plays an important role in regulation of the intracellular concentration of specific proteins in order to maintain the stability of the intracellular environment. Proteolytic affects intracellular multi-level signalling cascade. The disruption of the normal intracellular environment can lead to cell death while the inhibition of the 26S proteasome can prevent the hydrolysis of specific proteins. In vitro tests have proved bortezomib exhibits cytotoxicity to multiple types of cancer cells. The in vivo models of preclinical tumor have proved that bortezomib is capable of delaying the tumor growth of multiple myeloma which is suitable for the treatment of multiple myeloma.
The above information is edited by the Chemicalbook of Dai Xiongfeng.

Description

Bortezomib, a potent ubiquitin proteasome (26S) inhibitor (Ki=0.6 nM), was launched in the US as a treatment for multiple myeloma. This proteasome is required for the proteolytic degradation of the majority of cellular proteins and is present in all cells. It is required for the control of inflammatory processes, cell cycle regulation and gene expression and is a novel target in cancer treatment. Bortezomib is a N-acyl-pseudodipeptidyl boronic acid and formulated as a mannitol ester. Aldehyde containing peptides are also proteasome inhibitors, but lack chiral stability (racemization) and selectivity against other proteases including cysteine proteases. Replacement of the aldehyde moiety by a boronic acid avoids these shortcomings and provides some measure of selective proteasome inhibition relative to many other serine proteases. It is prepared by coupling the pinanediol ester of leucine boronic acid with N-tert-Bocphenylalanine utilizing O-(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) as the coupling agent. The tert-Boc protecting group is then cleaved from the dipeptide and pyrazinecarboxylic acid is coupled to form the terminal amide. Hydrolysis of the boronate ester is accomplished via a two-phase transesterification procedure using isobutyl boronic acid and aqueous extraction. In a study of patients who had received at least two prior therapies and demonstrated disease progression on their most recent therapy, about twenty eight percent showed a response to bortezomib. The response lasted a median time of one year. Another trial in 54 patients with relapsed multiple myeloma showed similar responses. It is dosed intravenously at an exposure of 1.3 mg/m2/dose twice weekly for two weeks followed by a 10-day drug-holiday. At therapeutic doses, the plasma drug levels were reported to drop to near detection limits within minutes of intravenous dosing. Based upon an ex vivo proteasome activity assay using blood cells, the pharmacodynamic half-life ranged from 9 to 15 h in patients with advanced malignancies.

Chemical Properties

Yellow Solid

Originator

Millenium (LeukoSite, Proscript) (US)

Uses

Bortezomib is the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. T

Definition

ChEBI: L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at Nalpha by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid tha reversibly inhibits the 26S proteasome.

brand name

Velcade (Millennium).

General Description

Proteasomes normally function to degrade proteins that areno longer needed by the cell. Such proteins are normallymarked by the addition of ubiquitin, a 76 amino acid proteinthat is added to the -amino group of lysine residues onthe target proteins. The marked proteins are then hydrolyzedby the large barrel-shaped proteasomes to givepeptides of 7 to 8 residues that may be further hydrolyzedand reutilized by the cell. This process serves to regulateprotein levels within the cell, remove defective proteins,and becomes important in maintaining normal signal transduction.Inhibition of the proteasomes results in the buildup of ubiquitylated proteins, which disrupts cell-signalingprocesses and cell growth. The signaling bytranscription factor NF-B (nuclear factor B) appears tobe especially sensitive to bortezomib. NF-B is associatedwith the transcription of antiapoptotic and proliferativegenes but is under the control of IB (inhibitor of NF-B).IB can itself be phosphorylated by IKK (IB kinase),which marks IB for ubiquitylation and destruction allowingNF-B to mediate its antiapoptotic and proliferative effects effects.In the presence of the competitive inhibitor bortezomib(IC50=0.6 nM), the 26S proteasome is inhibitedand the ubiquitylated IkB is still capable of inhibiting NF-kB, preventing its effects.

Pharmaceutical Applications

Bortezomib belong to the class of drugs called proteasome inhibitors and is licensed in the United States and the United Kingdom for the treatment of multiple myeloma. The drug has been licensed for patients in whom the myeloma has progressed despite prior treatment or where a bone marrow transplant is not possible or was not successful. It is marketed under the name Velcade? or Cytomib?. Velcade is administered via injection and is sold as powder for reconstitution.
Bortezomib was the first drug approved in the new drug class of proteasome inhibitors and boron seems to be its active element. For the mode of action, it is believed that the boron atom binds with high affinity and specificity to the catalytic site of 26S proteasome and inhibits its action. Therapy with Bortezomib can lead to a variety of adverse reactions, including peripheral neuropathy, myelosuppression, renal impairment and gastrointestinal (GI) disturbances together with changes in taste. Nevertheless, the side effects are in most cases less severe than with alternative treatment options such as bone marrow transplantation.

Chemical Synthesis

Although the synthesis of dipeptidyl boronic acids have appeared on several reports, the synthetic details for bortezomib were not revealed. The synthetic route for the preparation of bortezomib is depicted in the scheme.The pinanediol ester of leucine boronic acid (56)was coupled with N-Boc phenylalanine (57) in the presence of TBTU followed by deprotection of the Boc group to provide 58. N-Acylation of 58 then furnished the dipeptide boronate ester 60. Deprotection of the boronic ester functionality was achieved by bi-phase transfer esterification with isobutyl boronic acid. Bortezomib (VI) was isolated by extractive workup.

Bortezomib Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Bortezomib Suppliers

Jinan Yuantai Pharmaceutical Co.,Ltd
Tel
0531-69959492-
Fax
0531-88603458
Email
42660257@qq.com
Country
China
ProdList
87
Advantage
55
Jinan Baozhao Pharmaceutical Technology Co., Ltd.
Tel
0531-86397156
Fax
0531-82371858
Email
baozhaopharm@163.com
Country
China
ProdList
143
Advantage
58
Shandong Platinum Pharmaceutical Co., Ltd.
Tel
0531-88963280- ;531-88963280-
Fax
0531-88964879
Email
dwyane.wang@boyuanpharm.com;boyuanchem@126.com
Country
China
ProdList
106
Advantage
58
Jiangsu Vcare PharmaTech Co., Ltd.
Tel
025-58741518- ;025-58741518- ;025-58741518-
Fax
+86-25-58744115
Email
sales@vcarepharmatech.com;yue_meng@vcarepharmatech.com;sales07@vcarepharmatech.com
Country
China
ProdList
308
Advantage
61
Nanjing NingFan Pharm-Tech CO. LTD.
Tel
17368696818
Email
info@njnfpharm.com
Country
China
ProdList
1990
Advantage
58
Shenzhen SUNGENING Bio-Medical Co., Ltd.
Tel
0755-28967200-8056;0755-28967200-8062
Fax
0755-28967200
Email
hnsale203@sungening.com;wxf@sungening.com
Country
China
ProdList
9606
Advantage
60
Shanghai Fulland Pharmaceuticals Ltd
Tel
021-50432069-
Email
sales2@fullandpharma.com
Country
China
ProdList
35
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2926
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833- ;010-82848833-
Fax
86-10-82849933
Email
jkinfo@jkchemical.com;market6@jkchemical.com
Country
China
ProdList
96500
Advantage
76
INTATRADE GmbH
Tel
+49 3493/605464
Fax
+49 3493/605470
Email
sales@intatrade.de
Country
Germany
ProdList
3579
Advantage
66
More
Less

View Lastest Price from Bortezomib manufacturers

WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD
Product
Bortezomib 179324-69-7
Price
US $0.00/KG
Min. Order
100g
Purity
98%+
Supply Ability
100kg
Release date
2021-05-07
Hebei Yirun Sega Biological Technology Co. Ltd
Product
Bortezomib 179324-69-7
Price
US $0.30/g
Min. Order
100g
Purity
99.99%
Supply Ability
5ton/Month
Release date
2021-11-22
Hebei Zhanyao Biotechnology Co. Ltd
Product
Bortezomib 179324-69-7
Price
US $10.00/Kg/Bag
Min. Order
1Kg/Bag
Purity
99%
Supply Ability
20 Tons
Release date
2021-11-10

179324-69-7, BortezomibRelated Search:


  • Boronic acid, B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]bu
  • MG-341 PS-341
  • BortezoMib Base
  • BortezoMib-D8
  • bortezoMib(other)
  • MLM341
  • BortezoMib R
  • VELCADE(BORTEZOMIB)
  • Boronic acid, B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-
  • Bortezomib for research
  • Bortezomib ( Velcade, MG-341, PS-341 )
  • (R)-3-methyl-1-((S)-3-phenyl-2-(pyrazine-5-carboxamido)propanamido)butylboronic acid
  • BORTEZOMIB; MG-341; PS-341
  • BortezoMib(Velcade)
  • BortezoMib for res
  • BortezMib
  • 10MG/50MG/1G
  • N-pyrazinoyl-L-phenylalanine-L-boronoleucine
  • ((R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid
  • [(1S)-3-Methyl-1-[(2R)-3-phenyl-2-(pyrazin-2-ylforMaMido)propanaMido]butyl]boronic acid
  • Radiciol
  • Bortezomib (Intermediate in China ONLY)
  • CS-1886
  • BortezoMib (PS-341, LDP-341, MLM341)
  • BortezoMib (PS-341)
  • chloro-4-fluoro-phenyl)aMino]-6-nitro-7-[(S)-(tetrahydrofuran-3-yl)oxy]quinazolin
  • N-(2-Pyrazinecarbonyl)-L-phenylalanine-L-leucine boronic anhydride
  • B-[(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid
  • DPBA Bortezomib (PS-341)
  • Bortezomib [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid
  • EZSolution PS-341
  • Bortezomib, >=98%
  • VELCADE
  • dpba
  • BORTEZOMIB
  • [(1r)-3-methyl-1-[[(2s)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-boronic acid
  • 3-methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid
  • Bortezomib for Injection
  • Brotezamide
  • Bortezomib fandachem
  • Bortezomib USP/EP/BP
  • ortezomib
  • Bortezomib (10mM in DMSO)
  • 179324-69-7
  • 79324-69-7
  • C19H25BN4O4
  • peptides
  • Inhibitor
  • Final material
  • API
  • Pepetides
  • Apis
  • Boron Derivatives
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • ProteasomeInhibitors